BNP Paribas Financial Markets Raises Stake in ABIVAX Société Anonyme (NASDAQ:ABVX)

BNP Paribas Financial Markets grew its holdings in shares of ABIVAX Société Anonyme (NASDAQ:ABVX) by 82.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,044 shares of the company’s stock after purchasing an additional 5,900 shares during the quarter. BNP Paribas Financial Markets’ holdings in ABIVAX Société Anonyme were worth $150,000 at the end of the most recent quarter.

Separately, abrdn plc increased its stake in ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Performance

Shares of NASDAQ:ABVX opened at $7.94 on Wednesday. ABIVAX Société Anonyme has a 52 week low of $7.11 and a 52 week high of $17.02. The firm’s 50 day moving average is $9.40 and its two-hundred day moving average is $11.23.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. JMP Securities started coverage on ABIVAX Société Anonyme in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $33.00 price target on the stock. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $38.67.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.